登录  
 加关注
查看详情
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

青山妩媚

新的一年,新的心情,新的挑战,新的起点...

 
 
 

日志

 
 

R&D Spending: Numbers for Pfizer, J&J, Merck, Lilly and Bristol  

2010-01-20 21:05:30|  分类: Bio-Pharma |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |

R&D Spending: Numbers for Pfizer, J&J, Merck, Lilly and Bristol


By Jacob Goldstein

Pharmaceutical LabU.S. investment in R&D fell slightly this year, and is expected to start growing again next year, according to a new report out from the Battelle Memorial Institute, a nonprofit group that looks at that sort of thing.

A story in this morning’s WSJ has more on the issue; Health Blog readers may be particularly interested in some numbers from the report on R&D spending at big U.S. drug companies.

Of course, company-by-company figures like these don’t tell the whole story, in part because of the effects of consolidation. For example, Pfizer’s R&D spending may climb next year because of the Wyeth acquisition, but continuing cuts could mean the company’s R&D spending is lower than this year’s combined R&D spending for Pfizer and Wyeth.

Nevertheless, a numbers dump can still be interesting. Here it is:

R&D Spending, in millions of dollars

Company Q1-Q3, ‘08 Q1-Q3, ‘09 Change
Pfizer $5,642 $5,032 -10.8%
J&J $5,469 $4,773 -12.7%
Merck $3,419 $3,874 13.3%
Eli Lilly $2,782 $3,110 11.8%
Bristol-Myers Squibb $2,442 $2,590 6.1

Photo: Associated Press


  评论这张
 
阅读(318)| 评论(0)

历史上的今天

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2018